Large Cell and Small Cell Neuroendocrine Bladder Carcinoma

Serrano, Francisco Alijo; Sánchez-Mora, Nora; Arranz, José Ángel; Hernández, Carlos; Álvarez-Fernández, Emilio

doi:10.1309/htrem6qyqdygnwya

Cited by 70 publications

(30 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Coarse chromatin and frequent nucleoli, mitotic activity in excess of 10 mitoses per 10 high power fields and multiple areas of necrosis are also common [11]. …”

Section: Neuroendocrine Carcinoma Of the Bladder: Reviewmentioning

confidence: 99%

“…Immunohistochemical markers commonly used to demonstrate neuroendocrine differentiation, such as chromogranin, synaptophysin and neuron-specific enolase are variably expressed in SCCB [21] and can be also present in LCCB [11]. Thyroid transcription factor-1 can be also present in SCCB and LCCB [11].…”

Section: Neuroendocrine Carcinoma Of the Bladder: Reviewmentioning

confidence: 99%

“…Thyroid transcription factor-1 can be also present in SCCB and LCCB [11]. Cytological findings in urine samples of patients with SCCB are distinctive and an accurate diagnosis can be made.…”

Section: Neuroendocrine Carcinoma Of the Bladder: Reviewmentioning

confidence: 99%

“…In fact TMN stage was the only prognostic factor with a statistical significant relationship to survival [11]. The outcome was also relatively better for SCCB than for small cell lung carcinoma.…”

Section: Neuroendocrine Carcinoma Of the Bladder: Reviewmentioning

confidence: 99%

“…Large cell carcinoma of the urinary bladder (LCCB) was first reported in 1986 [4] and since then 17 more cases have been described on the literature [5,6,7,8,9,10,11,12,13,14,15,16]. Because of the relative rarity of these tumors there is no standard approach for managing SCCB [17] or LCCB [13].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Large Cell Neuroendocrine Carcinoma of the Urinary Bladder: Case Report and Review

2014

View full text Add to dashboard Cite

Introduction: Neuroendocrine carcinomas of the urinary bladder are relatively rare, accounting for less than 1% of all bladder carcinomas. These tumors can be divided into the more indolent typical or atypical carcinoid tumors and the aggressive small cell and large cell neuroendocrine carcinomas. Objective: To report 2 clinical cases of large cell neuroendocrine carcinoma of the bladder (LCCB) and to review the epidemiology, prognosis, and current treatment algorithms for patients with bladder small and large cell neuroendocrine carcinomas. Results: In both cases hematuria was the presenting symptom. One patient was submitted to partial cystectomy and the other to trans-urethral resection of the bladder tumor. The former patient died on the third month postoperatively. The latter patient had extensive liver metastasis at the time of diagnosis and died from acute liver failure on the 14th postoperative day. In review LCCB is associated with a more aggressive behavior and poorer prognosis than transitional cell bladder carcinoma. No standard approach exists. Surgery (transurethral ressection, partial cystectomy, radical cystectomy), chemotherapy and radiotherapy are current treatment modalities. Conclusion: LCCB is an aggressive tumor which usually presents itself in an advanced stage. Neoadjuvant chemotherapy with platinum regimen plus aggressive surgical approach should be the treatment of choice.

show abstract

“…Coarse chromatin and frequent nucleoli, mitotic activity in excess of 10 mitoses per 10 high power fields and multiple areas of necrosis are also common [11]. …”

Section: Neuroendocrine Carcinoma Of the Bladder: Reviewmentioning

confidence: 99%